WALTHAM, Mass.--(BUSINESS WIRE)--
NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it will join an
exclusive number of companies to participate in CES Unveiled, the
official press event of the International Consumer Electronics Show in
Las Vegas in January 2015.
Quell™ utilizes NeuroMetrix's proprietary non-invasive neurostimulation
technology to provide relief from chronic pain, particularly neuropathic
pain such as due to diabetes and lower back problems. The advanced
wearable device is lightweight and can be worn during the day while
active, and at night while sleeping. It has been cleared by the FDA for
treatment of chronic pain without a prescription. Users of the device
will also have the option of using their smartphone to automatically
track and personalize their pain therapy. The Company expects Quell™ to
be available for purchase by consumers in the second quarter of 2015.
"We are excited to preview the new Quell™ Wearable Pain Relief
Technology to the media at CES Unveiled," says Frank McGillin, SVP and
General Manager Consumer of NeuroMetrix. "We will be one of the few
wearable technology companies, and will have the opportunity to showcase
our unique wearable therapeutic innovation to over 1,200 global media
representatives."
About NeuroMetrix
NeuroMetrix is an innovative health-care company that develops wearable
medical technology and point-of-care tests that help patients and
physicians better manage chronic pain, nerve diseases, and sleep
disorders. For more information, please visit http://www.NeuroMetrix.com.
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and
Chief Financial Officer
neurometrix.ir@neurometrix.com
Source: NeuroMetrix, Inc.
News Provided by Acquire Media
